|
ATE466948T1
(de)
|
1997-03-11 |
2010-05-15 |
Univ Minnesota |
Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
|
|
WO2003089618A2
(en)
|
2002-04-22 |
2003-10-30 |
Regents Of The University Of Minnesota |
Transposon system and methods of use
|
|
CN101743249B
(zh)
|
2007-05-11 |
2017-08-08 |
阿尔托生物科学有限公司 |
融合分子与il‑15变异体
|
|
EP2160461B1
(en)
|
2007-07-04 |
2012-08-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Hyperactive variants of the transposase protein of the transposon system sleeping beauty
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
PT2692865E
(pt)
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
ES2836743T3
(es)
|
2014-06-02 |
2021-06-28 |
Us Health |
Receptores de antígeno quiméricos que seleccionan como diana CD-19
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
FI3240805T3
(fi)
|
2014-12-15 |
2025-02-17 |
Univ California |
Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
|
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
KR102615825B1
(ko)
|
2015-03-11 |
2023-12-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
전위효소 폴리펩타이드 및 이의 용도
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
US20190135894A1
(en)
|
2015-06-25 |
2019-05-09 |
iCell Gene Therapeuticics LLC |
COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
CN112481217A
(zh)
|
2016-09-01 |
2021-03-12 |
嵌合体生物工程公司 |
Gold优化的car t-细胞
|
|
EP3568474A1
(en)
*
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
CN108728459B
(zh)
*
|
2017-04-24 |
2023-08-04 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
|
|
DE112018002302B4
(de)
|
2017-05-02 |
2020-10-22 |
Chongqing Precision Biotech Company Limited |
Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
|
|
CA3065930A1
(en)
*
|
2017-06-07 |
2018-12-13 |
Intrexon Corporation |
Expression of novel cell tags
|
|
EP3673053A1
(en)
|
2017-08-21 |
2020-07-01 |
EMBL European Molecular Biology Laboratory |
Improved transposase polypeptide and uses thereof
|
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
|
CA3075619A1
(en)
|
2017-09-15 |
2019-03-21 |
Kite Pharma, Inc. |
Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
|
|
MY204419A
(en)
|
2017-10-31 |
2024-08-28 |
Servier Lab |
Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
|
|
IL316257A
(en)
*
|
2017-12-22 |
2024-12-01 |
Fate Therapeutics Inc |
Enhanced immune effector cells and use thereof
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US12331114B2
(en)
|
2018-02-13 |
2025-06-17 |
Indian Institute Of Technology Bombay |
Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
|
|
CN108383914A
(zh)
|
2018-02-23 |
2018-08-10 |
北京美康基免生物科技有限公司 |
一种基于cd19的嵌合抗原受体及其应用
|
|
EP3561053A1
(en)
*
|
2018-04-26 |
2019-10-30 |
Baylor College of Medicine |
Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
JP7611705B2
(ja)
|
2018-06-22 |
2025-01-10 |
ザ ジェネラル ホスピタル コーポレイション |
Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体
|
|
US12036242B2
(en)
|
2018-07-05 |
2024-07-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
CAR T cells that target B-cell antigens
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
EP3743512A4
(en)
|
2018-10-31 |
2021-12-01 |
Nantkwest, Inc. |
ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS
|
|
IL283218B2
(en)
|
2018-11-16 |
2025-11-01 |
Juno Therapeutics Inc |
Dosing methods of engineered T cells for the treatment of malignant B cells
|
|
CN109517799B
(zh)
|
2018-11-30 |
2022-07-26 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN113692285A
(zh)
|
2018-11-30 |
2021-11-23 |
朱诺治疗学股份有限公司 |
在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
|
|
CN109468284A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN110951689A
(zh)
|
2018-11-30 |
2020-04-03 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd30的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109468283A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
CN109880802B
(zh)
|
2018-11-30 |
2022-12-13 |
北京美康基免生物科技有限公司 |
一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
WO2020124021A1
(en)
|
2018-12-13 |
2020-06-18 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd79b and cd19
|
|
CN113874391B
(zh)
|
2019-02-20 |
2025-10-28 |
希望之城公司 |
靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
|
|
CN114502188B
(zh)
|
2019-02-21 |
2025-04-04 |
艾贝乐医药科技有限公司 |
人工免疫监视嵌合抗原受体及其表达细胞
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
SG11202111031RA
(en)
|
2019-04-26 |
2021-11-29 |
Allogene Therapeutics Inc |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
|
MX2021013359A
(es)
|
2019-04-30 |
2022-01-31 |
Crispr Therapeutics Ag |
Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
|
|
CN118593691A
(zh)
|
2019-05-03 |
2024-09-06 |
凯德药业股份有限公司 |
施用嵌合抗原受体免疫疗法的方法
|